gsk201102216k2.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending February 2011
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 



 
Notification of Transactions of Directors and Persons Discharging Managerial Responsibility
 
Vesting of awards made under the GlaxoSmithKline Share Value Plan in 2008
 
This notification sets out the vesting of Ordinary Shares made in 2008 under the GlaxoSmithKline Share Value Plan.
 
The three-year vesting period for the GlaxoSmithKline Share Value Plan awards made in 2008, which commenced on 1 January 2008, came to an end on 31 December 2010. The awards made to individuals who have subsequently been appointed Corporate Executive Team members, together with the Company Secretary, who are all Persons Discharging Managerial Responsibility (PDMR), are given in the table below.
 
Following the vesting of this award on 19 February 2011 the following shares were awarded:
 
 
 
No. of
Shares
Vested
Mr S M Bicknell
2,520
 
Mr D S Redfern
3,350
 
Ms C Thomas
2,520
 
    Mrs V A Whyte                                             
1,200
The Company and PDMRs were advised of these transactions on 21 February 2011.
 
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a)
 
V A Whyte
Company Secretary
 
21 February 2011



 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: February 21 2011
 
 
By: VICTORIA WHYTE
------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc